EE05603B1 - Alendronaadi kasutamine ravimi valmistamiseks osteoporoosi raviks - Google Patents

Alendronaadi kasutamine ravimi valmistamiseks osteoporoosi raviks

Info

Publication number: EE05603B1
Authority: EE; Estonia
Prior art keywords: alendronate; disclosed; osteoporosis; medicament; manufacture
Prior art date: 1997-07-22

Application number

EEP200000040A

Other languages

English (en)

Inventor

G. Daifotis Anastasia

C. Ii Santora Arthur

John Yates A.

Original Assignee

Merck & Co., Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-22

Filing date

1998-07-17

Publication date

2012-12-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05603(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-08-20 Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en

1997-08-22 Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en

1998-07-17 Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.

2000-10-16 Publication of EE200000040A publication Critical patent/EE200000040A/et

2012-12-17 Publication of EE05603B1 publication Critical patent/EE05603B1/et

Links

OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 title abstract 2
229940062527 alendronate Drugs 0.000 title abstract 2
208000001132 Osteoporosis Diseases 0.000 title 1
239000003814 drug Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
-1 etridronate Chemical compound 0.000 abstract 2
229940122361 Bisphosphonate Drugs 0.000 abstract 1
208000006386 Bone Resorption Diseases 0.000 abstract 1
MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 abstract 1
DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 abstract 1
230000002411 adverse Effects 0.000 abstract 1
150000004663 bisphosphonates Chemical class 0.000 abstract 1
230000024279 bone resorption Effects 0.000 abstract 1
ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 abstract 1
229960002286 clodronic acid Drugs 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000002496 gastric effect Effects 0.000 abstract 1
239000003485 histamine H2 receptor antagonist Substances 0.000 abstract 1
229940015872 ibandronate Drugs 0.000 abstract 1
LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 abstract 1
229950006971 incadronic acid Drugs 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 abstract 1
229940046231 pamidronate Drugs 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229940089617 risedronate Drugs 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
229940019375 tiludronate Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Compounds Of Unknown Constitution (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
Saccharide Compounds (AREA)
Hydrogenated Pyridines (AREA)
Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)

EEP200000040A 1997-07-22 1998-07-17 Alendronaadi kasutamine ravimi valmistamiseks osteoporoosi raviks EE05603B1 (et)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US5335197P	1997-07-22	1997-07-22
US5353597P	1997-07-23	1997-07-23
GBGB9717590.5A GB9717590D0 (en)	1997-08-20	1997-08-20	Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en)	1997-08-22	1997-08-22	Oral method for treating or preventing abnormal bone resorption
PCT/US1998/014796 WO1999004773A2 (en)	1997-07-22	1998-07-17	Method for inhibiting bone resorption

Publications (2)

Publication Number	Publication Date
EE200000040A EE200000040A (et)	2000-10-16
EE05603B1 true EE05603B1 (et)	2012-12-17

Family

ID=27451690

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200000040A EE05603B1 (et)	1997-07-22	1998-07-17	Alendronaadi kasutamine ravimi valmistamiseks osteoporoosi raviks

Country Status (31)

Country	Link
EP (5)	EP0998292B1 (et)
JP (2)	JP3479780B2 (et)
KR (3)	KR20030097610A (et)
CN (3)	CN1299689C (et)
AT (2)	ATE357921T1 (et)
AU (1)	AU8493698A (et)
BG (1)	BG66282B1 (et)
BR (1)	BR9810779A (et)
CA (1)	CA2294595C (et)
CY (2)	CY1107535T1 (et)
DE (6)	DE122006000009I1 (et)
DK (2)	DK1175904T3 (et)
EA (1)	EA004544B2 (et)
EE (1)	EE05603B1 (et)
ES (3)	ES2269014T3 (et)
HK (4)	HK1042230A1 (et)
ID (1)	ID24096A (et)
IL (1)	IL133535A0 (et)
IS (3)	IS5315A (et)
LU (2)	LU91222I2 (et)
NL (2)	NL300223I1 (et)
NO (1)	NO20000323L (et)
NZ (1)	NZ501807A (et)
PL (1)	PL195272B1 (et)
PT (2)	PT998292E (et)
SG (2)	SG139556A1 (et)
SI (1)	SI0998292T1 (et)
SK (1)	SK932000A3 (et)
TR (1)	TR200000145T2 (et)
UY (1)	UY25950A1 (et)
WO (1)	WO1999004773A2 (et)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1798700A (en)	1998-12-25	2000-07-31	Yamanouchi Pharmaceutical Co., Ltd.	Medicinal compositions for treating osseous lesion in multiple myeloma
DK1178810T3 (da) *	1999-05-21	2005-07-11	Novartis Ag	Anvendelse af bisphosphonsyrer til behandling af angiogenese
ES2337545T3 (es) *	1999-07-19	2010-04-27	Toray Industries, Inc.	Farmacos para enfermedades periodontales.
US20010044427A1 (en) *	1999-12-20	2001-11-22	Sidney Mazel	Pharmaceutical kit
WO2001046040A1 (en)	1999-12-20	2001-06-28	Merck & Co., Inc.	Blister package for pharmaceutical treatment card
JP2004517800A (ja) *	2000-04-07	2004-06-17	ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム	両性イオンリン脂質およびビスホスホネートを含む独特の組成物および胃腸毒性を低減化したビスホスフェートデリバリーシステムとしての該組成物の使用
SI1296689T1 (sl) *	2000-06-20	2006-08-31	Novartis Ag	Nacin dajanja pacientu bisfosfonatov
US8052987B2 (en)	2000-06-20	2011-11-08	Novartis Pharmaceuticals Corporation	Method of administering bisphosphonates
US6638920B2 (en) *	2000-07-21	2003-10-28	Merck & Co., Inc.	Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv)	2001-04-18	2001-04-18	Diabact Ab	Komposition som hämmar utsöndring av magsyra
PT1392325E (pt) *	2001-05-02	2006-10-31	Novartis Ag	Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose
KR20140021045A (ko) *	2002-05-10	2014-02-19	에프. 호프만-라 로슈 아게	골다공증 치료 및 예방용 비스포스폰산
SE0203065D0 (sv)	2002-10-16	2002-10-16	Diabact Ab	Gastric acid secretion inhibiting composition
KR20060058134A (ko) *	2003-09-19	2006-05-29	화이자 프로덕츠 인코포레이티드	2-알킬리덴-19-노르-비타민 디 유도체 및비스포스포네이트의 조합을 포함하는 약학 조성물 및 방법
WO2005072747A1 (ja) *	2004-02-02	2005-08-11	Ono Pharmaceutical Co., Ltd.	骨吸収抑制剤
CA2622322A1 (en) *	2005-09-16	2007-03-22	Selamine Ltd	Bisphosphonate formulation
ES2716525T3 (es) *	2010-12-06	2019-06-13	Effrx Pharmaceuticals Sa	Formulaciones de bisfosfonatos efervescentes estables con características de solubilización rápida
CN106924257B (zh) *	2017-03-14	2019-11-19	湖南赛隆药业有限公司	质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL84731A0 (en) *	1986-12-19	1988-05-31	Norwich Eaton Pharma	Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) *	1987-11-13	1987-11-13	Pm Konsult Handelsbolag	Anvendning av antisekretoriska substanser for nya indikationer
EP0521388B1 (de) *	1991-07-01	1995-05-10	Gerhard Dr. Gergely	Verfahren zur Herstellung einer pharmazeutischen Zubereitung mit wenigstens zwei verschiedenen Wirkstoffen und Verwendung einer solchen Zubereitung
AU661080B2 (en) *	1991-11-22	1995-07-13	Warner Chilcott Company, Llc	Risedronate delayed-release compositions
US5270365A (en) *	1991-12-17	1993-12-14	Merck & Co., Inc.	Prevention and treatment of periodontal disease with alendronate
US5294433A (en) *	1992-04-15	1994-03-15	The Procter & Gamble Company	Use of H-2 antagonists for treatment of gingivitis
HUT70210A (en) *	1992-06-30	1995-09-28	Procter & Gamble Pharma	Use of phosphonates for the treatment of osteoporosis
US5431920A (en) *	1993-09-21	1995-07-11	Merck Frosst, Canada, Inc.	Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) *	1994-04-21	1997-07-08	Merck & Co., Inc.	Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
CA2221416A1 (en) *	1995-06-06	1996-12-12	Merck & Co., Inc.	Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
JP2000511178A (ja) *	1996-05-17	2000-08-29	メルクエンドカンパニーインコーポレーテッド	発泡性ビスホスホネート製剤

1998
- 1998-07-17 EP EP98935752A patent/EP0998292B1/en not_active Revoked
- 1998-07-17 AU AU84936/98A patent/AU8493698A/en not_active Abandoned
- 1998-07-17 EE EEP200000040A patent/EE05603B1/et unknown
- 1998-07-17 CN CNB2004100557350A patent/CN1299689C/zh not_active Expired - Lifetime
- 1998-07-17 KR KR1020027013594A patent/KR20030097610A/ko not_active Ceased
- 1998-07-17 CN CNB988074737A patent/CN1166365C/zh not_active Ceased
- 1998-07-17 NZ NZ501807A patent/NZ501807A/en not_active IP Right Cessation
- 1998-07-17 DE DE1998603291 patent/DE122006000009I1/de active Pending
- 1998-07-17 JP JP50991499A patent/JP3479780B2/ja not_active Expired - Lifetime
- 1998-07-17 CN CNA2004100557346A patent/CN1602879A/zh active Pending
- 1998-07-17 AT AT01201913T patent/ATE357921T1/de active
- 1998-07-17 EP EP01201910A patent/EP1132088A3/en not_active Ceased
- 1998-07-17 ES ES01201913T patent/ES2269014T3/es not_active Expired - Lifetime
- 1998-07-17 DE DE69803291T patent/DE69803291T2/de not_active Revoked
- 1998-07-17 CA CA002294595A patent/CA2294595C/en not_active Expired - Fee Related
- 1998-07-17 EP EP01201913A patent/EP1175904B8/en not_active Revoked
- 1998-07-17 ES ES01201910T patent/ES2253136T1/es active Pending
- 1998-07-17 ES ES98935752T patent/ES2164447T3/es not_active Expired - Lifetime
- 1998-07-17 KR KR1020027013595A patent/KR20030097611A/ko not_active Ceased
- 1998-07-17 TR TR2000/00145T patent/TR200000145T2/xx unknown
- 1998-07-17 SK SK93-2000A patent/SK932000A3/sk not_active Application Discontinuation
- 1998-07-17 PL PL98338635A patent/PL195272B1/pl unknown
- 1998-07-17 DE DE01201911T patent/DE01201911T1/de active Pending
- 1998-07-17 DE DE01201913T patent/DE01201913T1/de active Pending
- 1998-07-17 PT PT98935752T patent/PT998292E/pt unknown
- 1998-07-17 KR KR1020007000680A patent/KR100391732B1/ko not_active Expired - Fee Related
- 1998-07-17 IL IL13353598A patent/IL133535A0/xx unknown
- 1998-07-17 AT AT98935752T patent/ATE209037T1/de active
- 1998-07-17 DE DE69837450T patent/DE69837450T2/de not_active Expired - Lifetime
- 1998-07-17 WO PCT/US1998/014796 patent/WO1999004773A2/en not_active Ceased
- 1998-07-17 EA EA200000151A patent/EA004544B2/ru not_active IP Right Cessation
- 1998-07-17 BR BR9810779-8A patent/BR9810779A/pt not_active Application Discontinuation
- 1998-07-17 EP EP01201912A patent/EP1175903A3/en not_active Ceased
- 1998-07-17 DK DK01201913T patent/DK1175904T3/da active
- 1998-07-17 EP EP01201911A patent/EP1151752A3/en not_active Ceased
- 1998-07-17 SI SI9830086T patent/SI0998292T1/xx unknown
- 1998-07-17 SG SG200603406-0A patent/SG139556A1/en unknown
- 1998-07-17 PT PT01201913T patent/PT1175904E/pt unknown
- 1998-07-17 ID IDW20000114A patent/ID24096A/id unknown
- 1998-07-17 DE DE200712000063 patent/DE122007000063I1/de active Pending
- 1998-07-17 DK DK98935752T patent/DK0998292T3/da active
- 1998-07-17 SG SG200107221A patent/SG109478A1/en unknown
1999
- 1999-12-21 IS IS5315A patent/IS5315A/is unknown
2000
- 2000-01-17 UY UY25950A patent/UY25950A1/es not_active Application Discontinuation
- 2000-01-18 BG BG104093A patent/BG66282B1/bg unknown
- 2000-01-21 NO NO20000323A patent/NO20000323L/no unknown
2002
- 2002-03-04 HK HK02101656.1A patent/HK1042230A1/en unknown
- 2002-03-12 HK HK02101869.4A patent/HK1042232A1/en unknown
- 2002-03-16 HK HK02102043.1A patent/HK1040495A1/en unknown
- 2002-03-16 HK HK02102042.2A patent/HK1040494A1/en unknown
2003
- 2003-03-10 JP JP2003063378A patent/JP2005068010A/ja active Pending
2004
- 2004-04-21 IS IS7231A patent/IS7231A/is unknown
- 2004-04-21 IS IS7230A patent/IS7230A/is unknown
2006
- 2006-02-07 NL NL300223C patent/NL300223I1/nl unknown
- 2006-02-15 LU LU91222C patent/LU91222I2/fr unknown
2007
- 2007-03-29 CY CY20071100442T patent/CY1107535T1/el unknown
- 2007-09-12 LU LU91364C patent/LU91364I2/fr unknown
- 2007-09-13 NL NL300292C patent/NL300292I1/nl unknown
- 2007-09-20 CY CY2007022C patent/CY2007022I2/el unknown

Also Published As

Publication number	Publication date
JP3479780B2 (ja)	2003-12-15
LU91364I2 (fr)	2007-11-12
SI0998292T1 (en)	2002-04-30
NL300223I1 (nl)	2006-04-03
EP1175904A2 (en)	2002-01-30
EP1175904B1 (en)	2007-03-28
NZ501807A (en)	2003-02-28
AU8493698A (en)	1999-02-16
ATE357921T1 (de)	2007-04-15
DE69803291T2 (de)	2002-08-08
IS7231A (is)	2004-04-21
EP0998292A2 (en)	2000-05-10
CY1107535T1 (el)	2012-01-25
BG104093A (en)	2000-10-31
PT1175904E (pt)	2007-04-30
EP1151752A3 (en)	2002-12-18
DE69837450T2 (de)	2007-08-23
IL133535A0 (en)	2001-04-30
CN1602879A (zh)	2005-04-06
HK1040494A1 (en)	2002-06-14
KR20030097611A (ko)	2003-12-31
EA004544B1 (ru)	2004-06-24
PL195272B1 (pl)	2007-08-31
EP1132088A2 (en)	2001-09-12
CN1166365C (zh)	2004-09-15
HK1042230A1 (en)	2002-08-09
DE69803291D1 (de)	2002-02-21
KR100391732B1 (ko)	2003-07-16
LU91222I2 (fr)	2006-04-18
JP2002502433A (ja)	2002-01-22
EA200000151A1 (ru)	2000-10-30
UY25950A1 (es)	2000-09-29
CN1265035A (zh)	2000-08-30
KR20010022110A (ko)	2001-03-15
EP1151752A2 (en)	2001-11-07
EP1175903A2 (en)	2002-01-30
PL338635A1 (en)	2000-11-06
DE69837450D1 (de)	2007-05-10
EP1175903A3 (en)	2002-12-18
KR20030097610A (ko)	2003-12-31
SG109478A1 (en)	2005-03-30
EP1175904B8 (en)	2007-05-09
WO1999004773A3 (en)	1999-04-15
CN1602880A (zh)	2005-04-06
ES2269014T3 (es)	2007-05-01
DE122007000063I1 (de)	2007-12-20
IS7230A (is)	2004-04-21
CA2294595C (en)	2001-08-21
CA2294595A1 (en)	1999-02-04
TR200000145T2 (tr)	2000-05-22
DK1175904T3 (da)	2007-05-07
EP1175904A3 (en)	2002-12-18
BG66282B1 (bg)	2013-01-31
DE01201911T1 (de)	2007-10-18
DE01201913T1 (de)	2007-02-08
ATE209037T1 (de)	2001-12-15
EP1132088A3 (en)	2002-04-24
ES2269014T1 (es)	2007-04-01
CY2007022I1 (el)	2012-01-25
ES2253136T1 (es)	2006-06-01
IS5315A (is)	1999-12-21
EA004544B2 (ru)	2006-12-29
HK1024166A1 (en)	2000-10-05
NO20000323D0 (no)	2000-01-21
SG139556A1 (en)	2008-02-29
HK1042232A1 (en)	2002-08-09
JP2005068010A (ja)	2005-03-17
WO1999004773A9 (en)	1999-10-28
ID24096A (id)	2000-07-06
CY2007022I2 (el)	2012-01-25
DE122006000009I1 (de)	2006-06-14
SK932000A3 (en)	2000-09-12
EE200000040A (et)	2000-10-16
PT998292E (pt)	2002-04-29
NO20000323L (no)	2000-03-20
BR9810779A (pt)	2000-07-25
EP0998292B1 (en)	2001-11-21
DK0998292T3 (da)	2002-05-13
CN1299689C (zh)	2007-02-14
NL300292I1 (nl)	2007-11-01
WO1999004773A2 (en)	1999-02-04
ES2164447T3 (es)	2002-02-16
HK1040495A1 (en)	2002-06-14

Legal Events

Date	Code	Title
2010-04-15	HC1A	Change of owner name
2012-12-17	GB1A	Change in the ownership or in the address of the owner
2012-12-17	HC1A	Change of owner name

Publication	Publication Date	Title
LU91364I2 (fr)	2007-11-12	Alendronate de sodium /colécalciférol
NZ545804A (en)	2009-09-25	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
HRP20020594B1 (en)	2011-03-31	Pharmaceutical parenteral composition containing a biphosphonate
DK0756484T3 (da)	2002-11-25	Vådgranuleringsformulering til diphosphonsyrer
BR0309691A (pt)	2005-08-02	Formulação de ibandronato em alta dose
YU1800A (sh)	2002-08-12	Upotreba bisfosfonata za proizvodnju leka za inhibiranje resorpcije kostiju
AR038041A1 (es)	2004-12-22	Metodo para el tratamiento de trastornos oseos
PE120399A1 (es)	2000-01-18	Composiciones que inhiben la resorcion osea